Skip to main content

Table 2 Results of meta-analyses evaluating the international normalized ratio stability in atrial fibrillation or venous thromboembolism patients

From: Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences

Meta-Analysis, Year

Population

TTR, % (95 % CI)

TBR, % (95 % CI)

TAR, % (95 % CI)

PINRR, % (95 % CI)

PINRBR, % (95 % CI)

PINRAR, % (95 % CI)

Mearns 2014

AF

61 (59 to 62)

25 (23 to 27)

14 (13 to 15)

59 (53 to 59)

26 (23 to 29)

13 (11 to 17)

Mearns 2014

VTE

61 (59 to 63)

25 (23 to 26)

15 (14 to 17)

59 (54 to 64)

26 (23 to 29)

13 (9 to 19)

Erkens 2012 (Month 1)

VTE

54 (NR)

42 (NR)

12 (NR)

NR

NR

NR

Erkens 2012 (Months 1–3)

56 (NR)

35 (NR)

19 (NR)

NR

NR

NR

Erkens 2012 (Month 1–6+)

60 (NR)

24 (NR)

17 (NR)

NR

NR

NR

Erkens 2012 (Month 4–12+)

75 (NR)

21 (NR)

12 (NR)

NR

NR

NR

Wan 2008 (RCT)

AF

67 (44 to 73)

20 (18 t to 40)

14 (9 to 17)

67 (48 to 84)

24 (14 to 32)

8 (2 to 24)

Wan 2008 (Prospective)

61 (56 to 66)

21 (14 to 29)

14 (13 to 30)

---

---

---

Wan 2008 (Retrospective)

59 (29 to 75)

25 (9 to 52)

14 (9 to 39)

53 (34 to 68)

26 (10 to 51)

17 (14 to 29)

Cios 2009

AF

59 (57 to 61)

NR

NR

NR

NR

NR

Reynolds 2004

AF

61 (NR)

26 (NR)

13 (NR)

61 (NR)

25 (NR)

14 (NR)

  1. AF atrial fibrillation, CI confidence interval, NR not reported, PINRAR proportion of INRs above range, PINRBR proportion of INRs below range, PINRR proportion of INRs in range; RCT randomized controlled trial, TAR time above range, TBR time below range, TTR time in range, VTE venous thromboembolism
  2. --- = evaluated, but no data